Impedimed Limited · ASX:IPD
Impedimed — H1 FY2024 Earnings Presentation
30 slides from Impedimed's earnings presentation, Feb 27, 2024
Slide 1: Investor Presentation cover letter to ASX
ImpediMed Limited 1/50 Parker Court Pinkenba, QLD, 4008 Australia E: investorrelations@impedimed.com W : impedimed.com 27 February 2024 For personal use only Companies Announcements Office Australian Securities Exchange Investor Presentation Further to the ImpediMed Limited’s (ASX:IPD) announcement
Slide 2: FY24 Investor Presentation Half-Year ended 31 December 2023
For personal use only FY24 Investor Presentation For the Half-Year ended 31 December 2023 Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. 1 ©2024 ImpediMed Limited.
Slide 3: Forward Looking Statements
Forward Looking Statements This presentation contains or may contain forward-looking statements that are based on ImpediMed Limited (ImpediMed) management’s For personal use only beliefs, assumptions and expectations and on information currently available to management. All statements that address o
Slide 4: Company Snapshot
Company Snapshot 12 month share trading performance For personal use only Issued capital Ordinary shares 2,023.3m Options / Performance Rights 75.0m Market capitalization* Share price $0.09 Market value A$212.4m Share register composition^ Institutional 38% Private/HNW 60% Board / Employees 2% Subst
Slide 5: Board of Directors
Board of Directors For personal use only Christine Emmanuel-Donnelly Dr Parmjot Bains McGregor Grant Janelle Delaney Andrew Grant Non-Executive Chair Managing Director / CEO CFO / Executive Director Non-Executive Director Non-Executive Director • IP expertise through • Extensive global healthcare •
Slide 6: Investment Highlights
Investment Highlights • Platform technology, unique clinical trial evidence demonstrating significant benefits to patients, definitive clinical guidelines supporting For personal use only BIS. • Increasing payor coverage across 14 states enables acceleration of the cancer–related lymphoedema device
Slide 7: CEO Plan on a Page
CEO Plan on a Page Vision Revolutionize patient care through clinically validated fluid and body mass composition BIS digital solutions For personal use only Goals Goal 1: Goal 2: Goal 3: Goal 4: Goal 5: Ensure every new US Deliver world-class Expand reach for all Reach break even Develop innovative
Slide 8: Foundation in Place for Success in Lymphoedema; Focus on Execution
Foundation in Place for Success in Lymphoedema; Focus on Execution Unique Technology BIS | SOZO | L-DEX For personal use only Strong Clinical Evidence PREVENT Trial Guidelines Supporting Standard of Care NCCN and multiple other guidelines Reimbursement 85% coverage expected by June 2024 Go-to-Market
Slide 9: SOZO Digital Health Platform: One device, multiple applications
SOZO® Digital Health Platform: One device, multiple applications A single SOZO measurement provides: For personal use only • L-Dex® lymphoedema analysis • Fat-free mass • HF-Dex heart failure analysis • Fat mass • Hy-Dex® hydration analysis • Skeletal muscle mass • Total body water • Protein and min
Slide 10: ImpediMed's Technology
ImpediMed’s Technology Using Bioimpedance Spectroscopy (BIS), SOZO non-invasively measures, monitors and manages fluid status and For personal use only tissue composition Subjective and Time Consuming BIS is Objective and Fast Imaging Low Frequency Current passes around cells Fluid Implantables 256
Slide 11: L-Dex Analysis for Lymphoedema
L-Dex® Analysis for Lymphoedema Designed for Lymphedema For personal use only The L-Dex® score is designed to detect lymphedema-related fluid changes in the arms. Accurate Detection L-Dex ® score is clinically validated to help detect lymphedema at its earliest, subclinical stage. Demonstrated Outco
Slide 12: Supported by Level Clinical Evidence taken into Guidelines
Supported by Level 1 Clinical Evidence taken into Guidelines Significantly lower progression to chronic lymphedema with early detection using L-Dex® and For personal use only intervention versus using Standard of Care (tape measure) • PREVENT Trial: multi-center, international RCT • n = 1,200 • 10 U
Slide 13: Guidelines Support Subclinical Detection, Intervention and BIS
Guidelines Support Subclinical Detection, Intervention and BIS National Comprehensive Cancer Network (NCCN®) Multinational Association of Supportive Care in Cancer For patients and survivors at risk for lymphedema: For breast cancer patients and survivors: For personal use only • Recommends regular
Slide 14: BIS Outperforms Other Lymphoedema Detection Methods
BIS Outperforms Other Lymphoedema Detection Methods Tissue Dielectric Multi-Frequency Bioimpedance Tape Measure Spectroscopy For personal use only Perometry Constant Bioimpedance Arm Volume MoistureMeter D, Analysis (MF-BIA) (BIS L-Dex) Lymphscanner InBody SOZO, U400 Specified for screening in NCCN
Slide 15: States at Critical Mass
14 States at Critical Mass2 - 7 high priority states at critical mass, additional 4 expected by April 2024 % Covered Lives1 WA For personal use only 80% or greater (Critical Mass) MT VT ME ND 70% or greater OR MN NH ID SD WI MI NY MA 60% or greater WY RI IA PA CT NV NE NJ 50% or OH UT IL IN greater
Slide 16: CEO Insights from the Field
CEO Insights from the Field Institutes and healthcare providers visited in first 6 Key insights weeks For personal use only • SOZO used primarily in BCRL (arms). • Across 8 states • Potential to expand in other cancer-related lymphoedema (plastics, pelvic • 18 providers, major IDNs to single sites o
Slide 17: Execute in BCRL with a World Class Customer Experience
Execute in BCRL with a World Class Customer Experience CURRENT U.S. SOZO FOOTFRINT NCCN INSTITUTIONS^ TOP 25 INTEGRATED DELIVERY NETWORKS^^ PRIORITIZED 11 STATES For personal use only 511 installed devices across 234 accounts 22 of 33 NCCN Customers 19 of 25 IDN Customers Execution Plan Focus custom
Slide 18: Market Opportunity
For personal use only Market Opportunity Company Confidential. ©2024 ImpediMed Limited. Internal Use Only. 17
Slide 19: Updated TAM Driven by Diagnoses, Tests Per Patient and Reimbursement
Updated TAM Driven by Diagnoses, Tests Per Patient and Reimbursement Rates Now Being Achieved Annual cancer diagnoses in the US by cancer type1 Economics of market driven by diagnoses, tests per patient and reimbursement rates For personal use only Breast 290,560 Breast Non-Breast All at-risk Cancer
Slide 20: BCRL is Most Advanced Indication for Commercialization
BCRL is Most Advanced Indication for Commercialization, Leg Commercial Strategy Being Accelerated Focus had been only on BCRL for last 12 months Now accelerating uptake for legs For personal use only Breast Cancer Related Lymphedema and Arm Cancer Related Lymphedema of the legs resulting from Melano
Slide 21: Create Additional Value and Customer Retention
For personal use only Create Additional Value and Customer Retention Company Confidential. ©2024 ImpediMed Limited. Internal Use Only. 20
Slide 22: SOZO Digital Health Platform Opportunity to Change Cancer Patient's Lives
SOZO Digital Health Platform Opportunity to Change Cancer Patient’s Lives Cancer population Opportunity to improve health outcomes for broader cancer For personal use only populations building on our device reach in cancer centers Many chronic diseases cause fluid shifts in the human body. Lymphoede
Slide 23: Significant Opportunities to Access New Patient Populations
Significant Opportunities to Access New Patient Populations 1.9M annual cancer diagnoses in the US1 Addressable market in Oncology is significant For personal use only • There are 1.9 million new cancer diagnoses in the US each year1 100% = 1.9M pa Breast 290,560 • ImpediMed’s current technology is
Slide 24: Commercial Business Cases and Partnering Models for New Indications
Commercial Business Cases and Partnering Models are Being Developed for New Indications, Adjacent to Oncology and Heart Failure Protein Calorie Malnutrition/Sarcopenia/Bone Mineral Content Heart Failure ✓ FDA Cleared for Protein Calorie Malnutrition ✓ FDA Cleared For personal use only ✓ Published cl
Slide 25: Rest of world strategy to be developed
Rest of world strategy to be developed, building on existing base 1,000+ For personal use only SOZO Systems deployed globally in Core Business1 Installed Base • US: 547 • EMEA: 75 • APAC: 419 1. The Core Business relates primarily to the Group’s Oncology business.. Proprietary, do not reproduce, dis
Slide 26: Financials
For personal use only Financials Company Confidential. ©2024 ImpediMed Limited. Internal Use Only. 25
Slide 27: FY24 Half-Year Financial Summary
FY24 Half-Year Financial Summary Highlights FY24 FY23 FY23 Change vs PH Change vs PY For personal use only $A millions 1H 2H 1H $ % $ % Revenue 4.8 5.7 5.7 (0.9) -16% (0.9) -15% • Revenue for the half-year was $4.8 million compared with $5.7 Gross profit 4.2 5.0 4.8 (0.8) -16% (0.7) -14% million in
Slide 28: Growing Installed Base and Increased Utilisation
Growing Installed Base and Increased Utilisation Base Driving Increased Patient Testing Global Installed Base SOZO Patient Tests For personal use only 44% 5-year CAGR1 U.S. Rest of World 1.Compound Annual Growth Rate Charts are not to scale and therefore are not comparable 27 Proprietary, do not rep
Slide 29: SaaS Metrics Shows Continuing Growth in ARR and Low Churn
SaaS Metrics Shows Continuing Growth in ARR and Low Churn SaaS Metrics For personal use only Core Business TCV1 Core Business ARR2 Churn3 3% Churn Rate based on SOZO Systems globally 1. Total Contracted Value (TCV) includes any consideration for the sale of SOZO Systems as well as the total Software
Slide 30: Summary
Summary • Best in class, innovative platform technology with early adopting world leading academic institutes in For personal use only our customer base. • Up to A$2bn TAM to test and treat all cancer-related limb lymphoedema. • Reimbursement remains critical for customer uptake and at >80% across 1